Quarterly report [Sections 13 or 15(d)]

Inventory

v3.26.1
Inventory
3 Months Ended
Feb. 28, 2026
Inventory Disclosure [Abstract]  
Inventory

Note 3 – Inventory

Inventory is comprised of public cord blood banking specimens, collection kits, finished goods, work-in-process and raw materials. Collection kits are used in the collection and processing of umbilical cord blood and cord tissue stem cells, finished goods include products purchased or assumed for resale and for the use in the Company’s processing and storage service. Inventory in the Public Cord Blood Bank includes finished goods that are specimens that are available for resale. The Company considers Public Cord Blood inventory in the Public Cord Blood Bank that has not completed all testing to determine viability to be work in process. Due to

changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of $4,358,834 was recognized during the fourth quarter of fiscal 2025 to reduce inventory to net realizable value.

The components of inventory at February 28, 2026 and November 30, 2025 are as follows:

 

 

 

As of
February 28, 2026

 

 

As of
November 30, 2025

 

Raw materials

 

$

 

 

$

 

Work-in-process

 

 

178,346

 

 

 

229,698

 

Work-in-process – Public Bank

 

 

 

 

 

 

Finished goods

 

 

120,725

 

 

 

131,777

 

Finished goods – Public Bank

 

 

802,896

 

 

 

803,274

 

Collection kits

 

 

38,742

 

 

 

27,763

 

Inventory reserve

 

 

(7,718

)

 

 

(7,718

)

Total inventory

 

$

1,132,991

 

 

$

1,184,794